12522 results for
Refine Your Search
Anti-Sox2 immunotherapy to prevent multiple myeloma relapse
Advances in multiple myeloma (MM) therapy have improved survival, but serial cycles of response and relapse still lead to and fatal disease in nearly…
Aileen Rowan
After completing a PhD in Immunology at Trinity College Dublin, I moved to Imperial College London to study how persistent infection with a virus caus…
Detection and treatment of Adult T cell leukemia/lymphoma in the premalignant stage.
Clonally expanded T cells carrying somatic mutations circulate in the premalignant phase of Adult T cell leukemia/lymphoma (ATL). We will develop of …
The Leukemia & Lymphoma Society Launches First-of-Its-Kind Global Master Clinical Trial for Pediatric Acute Leukemia
The global leader in the fight against blood cancers, The Leukemia & Lymphoma Society (LLS), announced the launch of its Pediatric Acute Leukemia (Ped…
News Release
The Leukemia & Lymphoma Society (LLS) Announces Board of Directors Officer Appointments; Welcomes New Board Member
The Leukemia & Lymphoma Society (LLS) Announces Board of Directors Officer Appointments; Welcomes New Board Member
News Release
Precision Medicine For DNMT3A-Mutant T-cell ALL
ALL is an aggressive blood cancer with poor overall survival, high relapse rates, and significant side effects. Using primary patient samples, this …
Sigurður Kristinsson
Professor Sigurður Yngvi Kristinsson is currently consolidating his position as one of the leading researchers in the field of multiple myeloma, its …
Early Detection and Intervention in Smoldering Multiple Myeloma: population-based screening and treatment; Edit-SMM
We build on the success from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study, where over , consented to a nationwide screeni…
Nitin Jain
Nitin Jain, MD, is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center in Houston. He earned his medical degree from the…
Combination Targeted Therapy in Chronic Lymphocytic Leukemia
Targeted therapies have replaced chemoimmunotherapy in chronic lymphocytic leukemia (CLL). We previously reported that combined BTK inhibitor (ibrutin…
Nirav Shah
Nirav Shah, MD, MSHP is currently an Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, special…
Improving Bispecific CD20/CD19 CAR T-cell Therapy to Overcome Resistance Mechanisms in B-cell Malignancies
The objective of this proposal is to improve bispecific / CAR activity and persistence by understanding impact of cell manufacturing parameters on fi…
Neha Mehta-Shah
Neha , MD, MSCI is an Assistant Professor of Medicine at Washington University in St. Louis where she specializes in peripheral and cutaneous lymphom…
Predictors of response to therapy in A051902, a US Intergroup study of duvelisib+CHO(E)P vs CC-486+CHO(E)P vs CHO(E)P in peripheral T-cell lymphoma
We are evaluating if adding duvelisib or azacitidine to standard chemotherapy increases the complete remission rate compared to chemotherapy alone in …
Tycel Phillips
I am a physician employed at the University of Michigan who specializes in the management of patients with a very specific blood cancer called lymphom…
Stratified treatment of newly diagnosed MCL based on the presence or absence of high risk features utilizing non-cytotoxic agents.
We believe that regimens without chemotherapy can induce significant and durable remissions in patients with Mantle cell lymphoma (MCL). We will confi…
Thomas LeBlanc
I am a oncologist and palliative care physician, Associate Professor of Medicine in the Duke University School of Medicine, and member of the Duke Ca…
Patient Experience Research and Palliative Care Integration in Malignant Hematology
My research aims to improve the patient and caregiver experience of blood cancer care. To achieve this, I conduct trials of integrated palliative care…
Understanding the clonal origin, evolution, and progression of myeloid malignancies
The overarching focus of my research is to understand the clonal origin, evolution, and progression of myeloid malignancies and biological and clinica…
Koichi Takahashi
Koichi Takahashi, MD, PhD is Associate Professor in the Departments of Leukemia and Genomic Medicine at The University of Texas MD Anderson Cancer Cen…
Luca Busino
The molecular mechanisms of cell proliferation and the field of Ubiquitin Proteasome System (UPS) have always been our main area of interest and fasci…
Relevance of ubiquitin dependent proteolysis in diffuse large B-cell lymphoma
The goal of this proposal is to investigate the significance of genes of the ubiquitin proteasome system (UPS) that are mutated in Diffuse Large Lymp…
Faron Pharmaceuticals Announces the Private Placement of EUR 5 Million, Including LLS TAP
TURKU, FINLAND / BOSTON, MA, June , - Faron Pharmaceuticals Ltd (First North: FARON, AIM: FARN), a clinical stage biopharmaceutical company focused o…
Paul
I have been very active with LLS for over years including: serving on the Wisconsin Chapter Board and Leadership Development Committee; fundraising f…
Living with Myeloma
Coleman Lindsley
Dr. Lindsley is an Assistant Professor of Medicine at Harvard Medical School and Cancer Institute. He received his M.D. and Ph.D.